The company will not receive any proceeds from the sale of the ordinary shares by the selling shareholders.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PYPD:
- PolyPid Launches Long-Acting GLP-1 Delivery Platform for Diabetes Market
- PolyPid Approves Key Resolutions at Annual Shareholder Meeting
- Analysts Predict Up to ~590% Spike for These 2 ‘Strong Buy’ Penny Stocks
- PolyPid price target lowered to $9 from $12 at Roth Capital
- PolyPid Secures $26.7 Million Post-Successful Phase 3 Trial